Stockscreener 앱 받기
3.87
2.65%
0.10
시간 외 거래:
3.90
0.03
+0.78%
전일 마감가:
$3.77
열려 있는:
$3.71
하루 거래량:
10.43M
Relative Volume:
0.69
시가총액:
$1.59B
수익:
$241.53M
순이익/손실:
$-389.92M
주가수익비율:
-3.1463
EPS:
-1.23
순현금흐름:
$-323.54M
1주 성능:
-4.91%
1개월 성능:
+35.79%
6개월 성능:
+88.78%
1년 성능:
+8.71%
1일 변동 폭
$3.61
$3.89
1주일 범위
$3.61
$4.21
52주 변동 폭
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.87 | 1.55B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 업그레이드 | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Zacks Research Issues Optimistic Forecast for IOVA Earnings - MarketBeat
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) latest press releases and corporate news - Yahoo Finance Singapore
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Gains Traction As Nasdaq Futures Reflect Biotech - Kalkine Media
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma - MSN
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Iovance Biotherapeutics Takes Steps Amidst Market Dynamics - timothysykes.com
What's going on with Iovance Biotherapeutics stock on Friday? - MSN
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance Biotherapeutics Inc (IOVA) Stock Price, Trades & News - GuruFocus
IOVANCE (NASDAQ: IOVA) CFO awarded 132,200 RSUs in equity grant - Stock Titan
235,000 RSUs granted to Iovance (NASDAQ: IOVA) interim CEO Frederick Vogt - Stock Titan
Equity grant: IOVANCE (NASDAQ: IOVA) awards 117,500 RSUs to Chief Regulatory Officer - Stock Titan
Iovance (NASDAQ: IOVA) CMO awarded 58,750 RSUs as equity compensation - Stock Titan
Iovance (NASDAQ: IOVA) COO awarded 117,500 RSUs over 3 years - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.5%What's Next? - MarketBeat
Iovance Biotherapeutics at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum - Sahm
Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan - Sahm
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com Nigeria
Iovance Biotherapeutics Shines with TIL Therapy Success and Financial Gain - timothysykes.com
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus - Yahoo Finance
Rhenman & Partners Asset Management AB Has $2.38 Million Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance (IOVA) Soars 33%, Hits All-Time High - Insider Monkey
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Finviz
Iovance (IOVA) hits 52-week high as analyst doubles price target - MSN
Momentum Shift: Is Iovance Biotherapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Naître et grandir
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum - International Business Times Australia
Iovance (NASDAQ: IOVA) CMO reports RSU vesting and tax share withholding - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax-share withholding - Stock Titan
Iovance (NASDAQ: IOVA) COO Bilinsky logs 31,246 RSUs vested and tax withholding shares - Stock Titan
Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum - Quiver Quantitative
Iovance Biotherapeutics Expands Clinical Trials Amid Strategic Upgrades - timothysykes.com
What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
Iovance Biotherapeutics Shines with Positive Trial Outcomes and Upgraded Ratings - StocksToTrade
UBS Raises PT on Iovance Biotherapeutics (IOVA) - Insider Monkey
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD By Investing.com - Investing.com Canada
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - The Motley Fool
Key facts: Iovance Biotherapeutics expands TIL therapy; UBS raises price target - TradingView
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $4.00 at UBS Group - MarketBeat
UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating - marketscreener.com
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):